行情

EXAS

EXAS

精密科学
NASDAQ

实时行情|Nasdaq Last Sale

65.39
+2.79
+4.46%
交易中 15:36 04/08 EDT
开盘
63.44
昨收
62.60
最高
65.77
最低
61.60
成交量
140.68万
成交额
--
52周最高
123.99
52周最低
35.25
市值
96.76亿
市盈率(TTM)
-91.9949
分时
5日
1月
3月
1年
5年

分析师评级

16位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EXAS价格均价为107.60,最高价位135.00,最低价为70.00。

EPS

EXAS 新闻

更多
  • Exact Sciences schedules first-quarter 2020 earnings call
  • PR Newswire · 8小时前
  • Exact Sciences: Well Positioned To Execute In FY20
  • Seeking Alpha - Article · 6天前
  • Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $90
  • Benzinga · 6天前
  • 10x Genomics Appoints Kim Popovits to Board of Directors
  • GlobeNewswire · 6天前

所属板块

生物技术和医学研究
+3.03%
制药与医学研究
+2.99%

热门股票

代码
价格
涨跌幅

EXAS 简况

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
展开

微牛提供EXACT Sciences Corporation(NASDAQ-EXAS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EXAS股票新闻,以帮助您做出投资决策。